Japanese stem-cell 'breakthrough' findings retracted By

New Post Public Reply Private Reply Replies (1) Message Board
Ospreyeye
Japanese stem-cell 'breakthrough' findings retracted
By James Gallagher

http://www.bbc.com/news/health-28124749

Research into one of the biggest recent stem-cell "breakthroughs" has been withdrawn because of "critical errors".

Scientists in Japan had claimed stem cells could be made cheaply, quickly and ethically just by dipping blood cells into acid.

They have now written a retraction that apologises for "multiple errors" in their report.

Nature, the journal that published the findings, is reviewing how it checks scientific papers.

Stem cells can become any other type of tissue and are already being investigated to heal the damage caused by a heart attack and to restore sight to the blind.

Researchers around the world described the acid-bath stem-cell finds as a "game changer," "remarkable" and "a major scientific discovery".

Falling apart
However, errors were rapidly discovered, parts were lifted from early work and presented as though it was new research, and leading scientists have been unable to produce stem cells using acid in their own laboratories.

An investigation by the Riken research institute in Japan found that scientist Dr Haruko Obokata had fabricated her work in an intentionally misleading fashion.

The retraction states: "These multiple errors impair the credibility of the study as a whole and we are unable to say without doubt whether the stimulus-triggered acquisition of pluri­potency stem cells phenomenon is real.

"Ongoing studies are investigating this phenomenon afresh, but given the extensive nature of the errors currently found we consider it appropriate to retract both papers."

The affair brings back memories of the false claims by world-renowned cloning scientists Hwang Woo-suk.

He claimed he had produced embryonic stem cells from cloned human embryos, but those findings were later found to be "intentionally fabricated".

'Highlighted flaws'
Jump media playerMedia player helpOut of media player. Press enter to return or tab to continue.
Archive: Dr Haruko Obokata presented the "breakthrough" findings in January
A Nature editorial stated that the public's trust in science was at stake in the latest controversy.

It added: "Although editors and referees could not have detected the fatal faults in this work, the episode has further highlighted flaws in Nature's procedures and in the procedures of institutions that publish with us."

However, it did say a review was under way to increase checking on images used in papers.

The acid-bath stem cells research has not been completely discredited and research is continuing to see if stem cells can be produced using the method.

Chris Mason, a professor of regenerative medicine at University College London, originally said the results were "a very exciting, but surprise, finding" and added: "It looks a bit too good to be true."

After the retraction, he told the BBC: "I'm surprised that Nature took so long when there was so much material showing problems with the papers. I don't understand that."

However, he said the system of peer review, in which fellow scientists critique papers before they are published, would struggle to pick up the problems in this research.

He said: "If you're a reviewer you can only review the material you're given. You have to take it on trust. You're not a detective looking for fraud.

'Good day for science'
"If you have to act as a super-sleuth, that's impossible for anyone to ever do."

He praised the way social media had uncovered and shared the errors, which could have otherwise taken years to unpick.

"I would argue this is not an embarrassing day for science, I think it's a good day for science and it shows we work well to weed out inferior publications."

Dr Dusko Ilic, a senior lecturer in stem-cell science at King's College London, said: "It is easy to be judgmental, and pointing fingers after all is over.

"Gaining knowledge is difficult. It requires both time and persistence, I hoped that Haruko Obokata would prove at the end all those naysayers wrong.

"Unfortunately, she did not. The technology, indeed, sounded too good to be true, though I still find fascinating how a 30-year-old scientist could pass scrutiny of her co-workers and multiple reviewers in Nature with a complete fabrication."

The UK Medical Research Council's Prof Robin Lovell-Badge added: "The stem cell community has been expecting these retractions to come for a while.

"This story illustrates how the stem cell field can rapidly detect bad science and reject it.

"It also illustrates both the problems and benefits of hype, this was potentially important research because of the novelty of the claims in an important field, but it was hyped far beyond reality, by some of the authors and by their perhaps willing victims, the media."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rosti Group Expands with Alvi Acquisition

Updated Category News Views 139

Rosti Bets on Expansion with Alvi Buyout Rosti Group just rolled the dice big by swallowing Alvi Group, marking another bold move in the ever-swinging industrial and medical device manufacturing rodeo. Suddenly, we’re talking about a company with roughly 3,000 employees on its roster and a neat EUR 450 million in combined revenue. Don't overlook the power play...

Continue Reading
Credit Union Teams Up for Holiday Toy Drive in San Diego

Updated Category News Views 0

San Diego's Seasonal Giving: A Community Effort Hold onto your hats, folks—it's that time of the year when giving isn't just a suggestion; it's a full-fledged community rallying cry. Heading into the joyful chaos is North Island Credit Union, teaming up with Boys & Girls Clubs of Greater San Diego to bring the spirit of the season to children across the region. Through...

Continue Reading
NextVision's Q3 2026: Impressive Growth and Expansion

Updated Category News Views 98

NextVision's financials this quarter are the envy of tech growth companies everywhere. Their Q3 2026 report reads like a thrilling playbook for success. No half-measures here—NextVision has doubled its revenue, slashed costs, and cooked up an operating margin fit for a kingpin. Pushing Revenue to New Heights NextVision didn’t just surpass last year's revenue; it...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 164

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Expedera Teams Up with Cadence for Edge AI Supercharge

Updated Category News Views 57

A New Power Couple in AI Expedera and Cadence have decided to stir up the edge AI waters with their latest collaboration. By linking Expedera's Origin™ Evolution NPU with Cadence's Tensilica NeuroEdge 130 AI Co-Processor, we're looking at a partnership that's hell-bent on redefining efficiency and performance in edge AI systems. Breaking Down the Collaboration This...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 119

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Bybit Expands On-Chain Access: Japanese Equity Focus

Updated Category News Views 71

Bybit's Bold Foray Into Japanese Equities Isn't every trader just itching to talk about Japan these days? Well, Bybit's got your back with its latest maneuvers. The platform is broadening its scope by diving headfirst into Japanese equities with a fresh offering—JPE backed by JX, no less. Bybit's RWA Earn platform isn't sticking to the boring fixed-income strategy...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 109

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Biond's BND-67 Trial: New Hope Against Tumors

Updated Category News Views 55

Turning Heads with a New Approach in Immunotherapy Right off the bat, let's say something's brewing in the world of cancer treatment, and it's got a promising name: BND-67. We're talking about Biond Biologics, an ambitious Israeli outfit aiming to rewrite the rules with their new kid on the block in immunotherapies. This isn't about business as usual. It's about a fresh...

Continue Reading
Foundayo Aims to Revolutionize Sleep Apnea Treatment

Updated Category News Views 81

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Continue Reading

Top 5 Most Recently Viewed Articles

Sulliden Mining Capital's Annual Meeting Results Unveiled

Updated Category News Views 159

Sulliden Mining Capital's Annual Meeting Results Unveiled On June 30, 2025, Sulliden Mining Capital Inc. (TSX: SMC) held its Annual and Special Meeting of Shareholders. This event followed the guidelines established by the Toronto Stock Exchange. During the meeting, shareholders engaged in an essential process—electing nominees presented in the management information...

Continue Reading
Ascential Medical's Dynamic Leadership Changes for Growth

Updated Category News Views 348

Leadership Changes at Ascential Medical & Life Sciences Ellen Scipta and Chris Cowen are stepping into pivotal roles as CFO and CCO at Ascential Medical & Life Sciences, while Todd Martensen transitions to the role of CSO. These changes reflect the company's commitment to innovation and strategic growth. Introducing Ellen Scipta: New Chief Financial Officer Ellen Scipta...

Continue Reading
Investors Target Xerox Holdings for Securities Class Action

Updated Category News Views 201

Legal Investigation of Xerox Holdings Corporation Faruqi & Faruqi, LLP, a highly regarded national securities law firm, is currently investigating potential claims involving Xerox Holdings Corporation (NASDAQ: XRX). Investors who have suffered significant financial losses are encouraged to reach out to discuss options available to them. Investor Losses and Legal Options...

Continue Reading
Understanding the Risks of Sharing Back-to-School Photos

Updated Category News Views 240

Understanding the Risks of Sharing Back-to-School Photos As families across the nation prepare for a new school year, there’s an important reminder from experienced investigator and child advocate, Moses Castillo. Before sharing those back-to-school photos on social media, it's crucial to consider the potential dangers associated with such posts. The Hidden Dangers of...

Continue Reading
Intel's Journey: Overcoming Two Decades of Market Struggles

Updated Category News Views 111

Intel's Long Road to Recovery Intel has faced significant challenges over the past two decades. Its stock performance has been lackluster, rising only 2% compared to the NASDAQ 100, which has surged over 1,200%. This stark contrast raises questions about Intel's strategic decisions and future direction. Intel's leadership has stumbled in crucial areas that have allowed...

Continue Reading